Table 3.
Demographical effects between impaired and spared cluster and healthy controls in discovery and validation sample.
| Impaired | Spared | Overall | Impaired vs. spared | Impaired vs. HC | Spared vs. HC | |||
|---|---|---|---|---|---|---|---|---|
| Mean (sd) | Mean (sd) | T(max)/Z | p (uncorr) | p (FDR) | p (FDR) | p (FDR) | p (FDR) | |
| Discovery | ||||||||
| N | 41 | 67 | ||||||
| Age | 23.5 (4.3) | 25.8 (5.4) | 2.015 | 0.106 | 0.109 | – | – | – |
| Years of Education | 13.5 (3.2) | 14.5 (3.3) | 4.612 | <0.001 | <0.001*** | 0.135 | <0.001*** | 0.002** |
| Sexa | female = 16 | female = 19 | 25.611 | <0.001 | <0.001*** | 0.302 | 0.009** | <0.001*** |
| Sitea,b | 11/5/11/5/9 | 28/15/17/3/4 | 23.614 | 0.003 | 0.003** | 0.046* | 0.061 | 0.014* |
| Ìllness duration in daysc | 163.66 (153.82) | 192.43 (205.69) | −0.770 | 0.440 | 0.440 | – | – | – |
| Chlorpromazine equivalentd | 685.65 (1596.42) | 196.95 (125.38) | 1.940 | 0.052 | 0.100 | – | – | – |
| Validation | ||||||||
| N | 13 | 40 | ||||||
| Age | 24.2 (5.3) | 26.2 (6.7) | 0.899 | 0.630 | 0.673 | – | – | – |
| Years of Education | 14.3 (3.7) | 14.0 (3.5) | 3.594 | <0.001 | 0.001** | 0.858 | 0.081 | 0.001** |
| Sexa | Female = 5 | Female = 16 | 8.575 | 0.014 | 0.016* | 1.000 | 0.140 | 0.017* |
| Illness duration in daysc | 149.00 (91.46) | 198.53 (228.55) | −0.761 | 0.447 | 0.535 | – | – | – |
| Chlorpromazine equivalentd | 127.80 (267.83) | 1578.48 (6006.66) | −0.833 | 0.405 | 0.535 | – | – | – |
HC healthy control, sd standard deviation, FDR False Discovery Rate.
aNominal permutation test are used; Fisher’s exact p value is reported.
bSites: Munich/Basel/Köln/Udine/Milan.
cDifference in time between first fulfillment of psychotic diagnosis according to Structured Clinical Interview for DSM-IV (SCID) and date of MRI examination.
dCumulative sum of chlorpromazine equivalents divided by the number of days treated.
*p < 0.05, **p < 0.01, ***p < 0.001.